Sorrento Therapeutics (SRNE) Competitors $0.0043 0.00 (-24.56%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsInsider TradesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRNE vs. CDT, CPHI, PALI, INM, VIVS, OGEN, TTNP, GLTO, XBIO, and CMNDShould you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include Conduit Pharmaceuticals (CDT), China Pharma (CPHI), Palisade Bio (PALI), InMed Pharmaceuticals (INM), VivoSim Labs (VIVS), Oragenics (OGEN), Titan Pharmaceuticals (TTNP), Galecto (GLTO), Xenetic Biosciences (XBIO), and Clearmind Medicine (CMND). These companies are all part of the "pharmaceutical products" industry. Sorrento Therapeutics vs. Its Competitors Conduit Pharmaceuticals China Pharma Palisade Bio InMed Pharmaceuticals VivoSim Labs Oragenics Titan Pharmaceuticals Galecto Xenetic Biosciences Clearmind Medicine Sorrento Therapeutics (NASDAQ:SRNE) and CDT Equity (NASDAQ:CDT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability. Which has preferable valuation & earnings, SRNE or CDT? CDT Equity has lower revenue, but higher earnings than Sorrento Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSorrento Therapeutics$60.32M0.04-$572.84MN/AN/ACDT EquityN/AN/A-$17.80M-$435.000.00 Is SRNE or CDT more profitable? Company Net Margins Return on Equity Return on Assets Sorrento TherapeuticsN/A N/A N/A CDT Equity N/A N/A -350.23% Do insiders and institutionals hold more shares of SRNE or CDT? 0.0% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 3.3% of CDT Equity shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by insiders. Comparatively, 7.7% of CDT Equity shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media refer more to SRNE or CDT? In the previous week, Sorrento Therapeutics' average media sentiment score of 0.00 equaled CDT Equity'saverage media sentiment score. Company Overall Sentiment Sorrento Therapeutics Neutral CDT Equity Neutral Which has more volatility & risk, SRNE or CDT? Sorrento Therapeutics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, CDT Equity has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500. SummaryCDT Equity beats Sorrento Therapeutics on 4 of the 6 factors compared between the two stocks. Get Sorrento Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRNE vs. The Competition Export to ExcelMetricSorrento TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.37M$283.48M$5.82B$9.74BDividend YieldN/AN/A3.84%4.09%P/E RatioN/AN/A31.1525.97Price / Sales0.04563.89475.57123.18Price / CashN/A22.4437.1558.38Price / BookN/A10.439.116.39Net Income-$572.84M-$115.81M$3.26B$265.66M7 Day PerformanceN/A-0.61%2.11%1.98%1 Month PerformanceN/A-4.58%5.12%1.33%1 Year PerformanceN/A-8.01%31.25%21.15% Sorrento Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRNESorrento Therapeutics0.716 of 5 stars$0.00-24.6%N/A-43.0%$2.37M$60.32M0.00800CDTConduit Pharmaceuticals0.1373 of 5 stars$1.57-4.3%N/A-99.3%$4.80MN/A0.003CPHIChina Pharma0.9256 of 5 stars$1.47+2.8%N/A-92.7%$4.80M$4.30M0.00250Gap UpPALIPalisade Bio2.5619 of 5 stars$0.80flat$12.00+1,398.1%-79.7%$4.74M$250K-0.2010Gap DownINMInMed Pharmaceuticals1.2259 of 5 stars$2.30-0.9%N/A-73.6%$4.65M$4.60M-0.1910Positive NewsVIVSVivoSim LabsN/A$1.81+2.3%N/AN/A$4.60M$142K-0.1820OGENOragenics0.4664 of 5 stars$1.10-4.3%N/A-96.2%$4.54MN/A-0.165Short Interest ↓TTNPTitan Pharmaceuticals0.3168 of 5 stars$5.18+5.1%N/A-40.0%$4.51M$180K-1.7610GLTOGalecto3.7441 of 5 stars$3.37-0.3%$10.00+196.7%-77.5%$4.48MN/A-0.2640News CoveragePositive NewsShort Interest ↓Gap DownXBIOXenetic Biosciences0.9684 of 5 stars$2.91+1.7%N/A-31.3%$4.41M$2.50M-1.454Short Interest ↑CMNDClearmind Medicine0.869 of 5 stars$1.02-1.0%N/A-22.5%$4.39MN/A-0.93N/APositive News Related Companies and Tools Related Companies Conduit Pharmaceuticals Competitors China Pharma Competitors Palisade Bio Competitors InMed Pharmaceuticals Competitors VivoSim Labs Competitors Oragenics Competitors Titan Pharmaceuticals Competitors Galecto Competitors Xenetic Biosciences Competitors Clearmind Medicine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRNE) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sorrento Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access